Search Bar & Filters
Found 37 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating the effects of autogenous grafts taken from different palatal regions on the tissue around dental implants during second-stage implant surgery. The study aims to compare how these grafts affect the width and thickness of the peri-implant mucosa, including tissue health and patient satisfaction. This evaluation involves clinical, radiographic, and digital methods to understand early effects on peri-implant soft tissue management. Participants are randomly assigned to one of two groups one receiving grafts including marginal and interdental palatal gingiva, and the other receiving grafts harvested about 1.5 mm apical to the palatal gingival margin. These grafts are applied during the second-stage implant surgery. The study uses a double-blind design to compare these two grafting techniques and their impact on the peri-implant mucosa. Participants will undergo assessments before implant placement, at the second-stage surgery 3 months, 6 months after implant placement, and 12 months after prosthetic loading. Evaluations include mucosal thickness and width, vestibular depth, plaque and bleeding indices, probing depth, mucosal recession, bone level, esthetic scores, pain, analgesic use, patient satisfaction, esthetic outcome, and oral health quality of life. The study involves clinical visits and monitoring of tissue changes and patient-reported outcomes over about one year after implant loading.
Actively Recruiting
Researchers are evaluating two measures to improve the surgical field during vaginal natural orifice transluminal endoscopic surgery vNOTES hysterectomy, a procedure performed entirely through the vagina without abdominal incisions. The study is a randomized trial using a 2x2 factorial design to test whether a preoperative low-residue diet for three days, deeper intra-operative muscle relaxation deep neuromuscular blockade, or their combination improve visualization by reducing bowel interference. This trial focuses on benign gynecological conditions such as uterine leiomyoma, abnormal bleeding, uterine prolapse, and adenomyosis. Participants are assigned equally to one of four groups no diet with standard relaxation, diet with standard relaxation, no diet with deep relaxation, or diet with deep relaxation the bundle. Deep neuromuscular blockade is maintained by continuous rocuronium infusion, while standard relaxation uses intermittent rocuronium boluses both groups receive reversal with sugammadex before extubation. The low-residue diet restricts fiber intake to less than 10 grams daily for three days before surgery, avoiding raw fruits, vegetables, legumes, nuts, and seeds but allowing refined grains and cooked foods. No mechanical bowel preparation is used in any group. During surgery, the surgical field is assessed objectively by lowering carbon dioxide insufflation pressure stepwise from 12 to 6 mmHg while blinded assessors score video clips for field adequacy. Researchers measure the lowest pressure at which the surgical field remains adequate as the primary outcome. Secondary measures include continuous field scores, need for additional instruments, postoperative nausea and vomiting, operative time, blood loss, and complications. Participants are monitored during surgery and up to 24 hours postoperatively, with full neuromuscular recovery confirmed before extubation.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether a psychoeducation program using digital storytelling can impact loneliness and self-efficacy in adults aged 65 to 74. Participants are randomly assigned to either the program group or a comparison group, and the study compares loneliness and self-efficacy outcomes between these groups. This research aims to understand the supportive care effects of this digital intervention on older adults. The study delivers a psychoeducation program through digital storytelling, consisting of six sessions lasting 30 minutes each. Participants in the experimental group attend these sessions, while those in the control group do not receive the intervention but complete the same assessments at matched time points. This randomized, single-masked trial runs from September 2026 to March 2027. Participants will complete evaluations of loneliness and self-efficacy before the program, immediately after completing the six sessions, and again three months post-program. The primary outcomes measured are changes in scores on the Older Adults Loneliness Scale and the General Self-Efficacy Scale. The study team monitors these measures to assess the programs impact over time, with total participation spanning several months including follow-up assessments.
Actively Recruiting
Researchers are evaluating the use of drug-coated balloons DCBs in treating various types of coronary artery disease, including in-stent restenosis, small vessel disease, de novo lesions, chronic total occlusions, and bifurcation lesions. This observational registry aims to gather real-world data on the safety, feasibility, and clinical outcomes of DCB angioplasty across diverse coronary lesion types and patient presentations in Turkey. The study seeks to provide comprehensive evidence beyond traditional uses, addressing both short- and long-term success rates. The study includes patients undergoing percutaneous coronary intervention PCI where DCBs are used either alone or with bailout stenting. Detailed information about patient demographics, clinical history, angiographic and procedural details, lesion preparation methods, intravascular imaging, and DCB characteristics will be collected. The registry will analyze procedural success and clinical outcomes such as major adverse cardiovascular events and need for further revascularization, focusing also on the role of lesion preparation and imaging guidance. Participants will be followed for at least 12 months, with data collected on death, revascularization of target lesions and vessels, myocardial infarction, bleeding events, and procedural success. Researchers will monitor clinical progress, collect angiographic and procedural data, and evaluate outcomes to identify factors influencing success or failure of DCB use. This study reflects routine clinical practice and aims to inform future randomized trials comparing DCB strategies with drug-eluting stents.
Actively Recruiting
This research aims to determine how bathing affects physiological measures such as heart rate, body temperature, oxygen levels, skin condition, bilirubin levels, and comfort in newborn infants receiving phototherapy for jaundice. Phototherapy is the common treatment for neonatal jaundice, which occurs frequently in newborns and can lead to serious complications if untreated. The study explores whether bathing before phototherapy can reduce side effects like skin rashes and improve infant comfort. The study compares two groups of newborns those who receive a bathtub bath before phototherapy and those who receive standard care without additional bathing. Phototherapy treatment involves exposing infants to light to lower bilirubin in the blood. The bathing method studied involves using a baby bathtub and baby shampoo. The experimental group gets the bath before starting phototherapy, while the control group follows routine care without extra intervention. Participants will be monitored with multiple assessments including heart rate, respiratory rate, body temperature, oxygen saturation, skin moisture, and skin condition scores at several time points before and after bathing or phototherapy treatment. Bilirubin levels will be measured before treatment and 24 hours after phototherapy begins. Comfort levels will also be evaluated at set intervals. The study runs from hospitalization through six hours post-intervention, with detailed physiological and skin condition tracking to assess the effects of bathing on infants receiving phototherapy.
1-10 of 37
1